What is it about?
Avelumab is the first drug approved for the treatment of metastatic Merkel cell carcinoma, This review provides a brief summary of the clinical management, discusses the role of avelumab and immunotherapy and identifies new treatment strategies in clinical development for patients with Merkel cell carcinoma.
Featured Image
Read the Original
This page is a summary of: Avelumab and Other Recent Advances in Merkel Cell Carcinoma, Future Oncology, October 2017, Taylor & Francis,
DOI: 10.2217/fon-2017-0305.
You can read the full text:
Contributors
The following have contributed to this page
